Stock Track | Verona Pharma Soars 7.05% in Pre-Market on Strong Ohtuvayre Sales and Phase 2 Pipeline Progress

Stock Track

Feb 27, 2025

Verona Pharma plc (NASDAQ: VRNA) shares surged 7.05% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales of its COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.

The key highlights from Verona Pharma's financial report include:

Net sales of Ohtuvayre, the company's first commercial product, reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024.
Verona Pharma initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.
The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment.

Verona Pharma's CEO, David Zaccardelli, expressed optimism about the strong launch of Ohtuvayre and the potential for ensifentrine to redefine the treatment paradigm for COPD. The company is also progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121601841"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121601841\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121601841?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121601841","market":"hk","top_or_hot":-1,"title":"Stock Track | Verona Pharma Soars 7.05% in Pre-Market on Strong Ohtuvayre Sales and Phase 2 Pipeline Progress","media":"Stock Track","content":"<p>Verona Pharma plc (NASDAQ: VRNA) shares surged 7.05% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales of its COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>The key highlights from Verona Pharma's financial report include:\n<ul>\n<li>Net sales of Ohtuvayre, the company's first commercial product, reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024.</li>\n<li>Verona Pharma initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</li>\n<li>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment.</li>\n</ul>\n</p>\n\n<p>Verona Pharma's CEO, David Zaccardelli, expressed optimism about the strong launch of Ohtuvayre and the potential for ensifentrine to redefine the treatment paradigm for COPD. The company is also progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Soars 7.05% in Pre-Market on Strong Ohtuvayre Sales and Phase 2 Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Soars 7.05% in Pre-Market on Strong Ohtuvayre Sales and Phase 2 Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 22:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Verona Pharma plc (NASDAQ: VRNA) shares surged 7.05% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales of its COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>The key highlights from Verona Pharma's financial report include:\n<ul>\n<li>Net sales of Ohtuvayre, the company's first commercial product, reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024.</li>\n<li>Verona Pharma initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</li>\n<li>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment.</li>\n</ul>\n</p>\n\n<p>Verona Pharma's CEO, David Zaccardelli, expressed optimism about the strong launch of Ohtuvayre and the potential for ensifentrine to redefine the treatment paradigm for COPD. The company is also progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1121601841","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121601841","pubTimestamp":1740665556,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Verona Pharma plc  shares surged 7.05% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales of its COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.The key highlights from Verona Pharma's financial report include:. Net sales of Ohtuvayre, the company's first commercial product, reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024.Verona Pharma initiated two Phase 2 trials in Q3 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"由于Ohtuvayre销售强劲和第二阶段管道进展，Verona Pharma盘前飙升7.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Verona Pharma plc (NASDAQ: VRNA) shares surged 7.05% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales of its COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.\nThe key highlights from Verona Pharma's financial report include:\n\nNet sales of Ohtuvayre, the company's first commercial product, reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024.\nVerona Pharma initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.\nThe company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment.\n\nVerona Pharma's CEO, David Zaccardelli, expressed optimism about the strong launch of Ohtuvayre and the potential for ensifentrine to redefine the treatment paradigm for COPD. The company is also progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}